September 12, 2016 — Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.
Venous disease affects millions of people worldwide and is marked by symptoms that include progressive leg pain and swelling, leg heaviness and skin changes. Physicians may choose to treat the obstructive component of venous disease through minimally-invasive endovascular stenting procedures.
The Vici Venous Stent System was designed from inception to meet the unique challenges of the venous system, providing physicians with a balance of crush resistance, flexibility and ease of deployment.
Citigroup Global Markets Inc. acted as exclusive financial advisor to Veniti in connection with the transaction.
For more information: www.veniti.com
July 18, 2024 
